24-10-14 PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration CI
24-07-22 PharmAbcine Inc. announced that it has received KRW 25.9761082 billion in funding from Tirebank Co., Ltd. CI
24-07-16 PharmAbcine Inc. announced that it has received KRW 4.416445599 billion in funding CI
24-07-16 PharmAbcine Inc. announced that it has received KRW 25.9761082 billion in funding from Tirebank Co., Ltd. CI
24-07-08 PharmAbcine Announces Safety Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors CI
24-07-02 PharmAbcine Inc. announced that it expects to receive KRW 25.9761082 billion in funding from Tirebank Co., Ltd. CI
24-07-01 PharmAbcine Inc. Announces its Phase 1 Clinical Trial of PMC-403 for Neovascular Age-Related Macular Degeneration Advances to Both Single-Dose of 4mg and Multiple-Dose of 3mg CI
24-06-27 PharmAbcine Inc. announced that it has received KRW 4.6500069 billion in funding from Tirebank Co., Ltd. and other investors CI
24-06-13 PharmAbcine Inc. announced that it expects to receive KRW 3.7117955 billion in funding CI
24-06-11 PharmAbcine Inc. announced that it expects to receive KRW 4.6500069 billion in funding from Tirebank Co., Ltd. and other investors CI
24-01-23 PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors CI
23-12-25 PharmAbcine Inc. announced that it has received KRW 5.000000492 billion in funding CI
23-11-30 PharmAbcine Inc. announced that it has received KRW 30.000001149 billion in funding from Hpbiolab Inc. CI
Manager TitleAgeSince
Chief Executive Officer 49 2024-08-01
Chief Tech/Sci/R&D Officer 45 2024-09-26
Director TitleAgeSince
Director/Board Member 62 -
Director/Board Member 53 -
Director/Board Member 49 2024-08-01
Date Insider Type Main position Quantity % Market Cap.
7/31/24 Others 1,000,000 3.3111%
7/31/24 Others 12,227,312 40.4863%
7/31/24 Others 562,697 1.8632%
Change 5-day change 1-year change 3-year change Capi.($)
-33.53%-34.29% - - 6.2M
-1.90%+11.59%+62.29%+102.60% 71.56B
-3.21%-3.13%+32.57%+60.59% 54.43B
-2.05%-6.65%+0.71%+451.67% 27.59B
-1.27%+9.09%+46.56%+4.13% 23.91B
+1.05%+2.08%-17.46%-12.93% 23.14B
+0.10%+7.99%+41.01%-20.48% 18.65B
+3.81%+16.28%+270.78%+488.06% 18.64B
-0.95%+2.46%+24.40%+574.22% 16.01B
+1.24%-1.84%+33.13%+138.10% 12.54B
Average -3.67%+2.96%+54.89%+198.44% 29.61B
Weighted average by Cap. -1.13%+1.72%+50.96%+159.65%
Logo PharmAbcine Inc.
PharmAbcine Inc. is a Korea-based company mainly engaged in the research and development of biopharmaceuticals. The Company researching and developing antibody therapeutics to provide patients with the antibodies needed to cure the disease. The Company’s major products include tanibirumab used for cancer treatment, among others. The Company also carries out technology transfer about its pipelines with domestic and overseas pharmaceutical companies.
Employees
37
  1. Stock Market
  2. Stocks
  3. A208340 Stock